Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Fund Type: Open-End Fund
  • Objective: Growth Mid Cap
  • Asset Class: Equity
  • Geographic Focus: U.S.

Dreyfus/The Boston Small/Mid Cap Growth Fund

+ Add to Watchlist

DBMAX:US

18.08 USD 0.20 1.12%

As of 09:29:30 ET on 05/27/2015.

Snapshot for Dreyfus/The Boston Small/Mid Cap Growth Fund (DBMAX)

Year To Date: +8.13% 3-Month: +3.20% 3-Year: +18.59% 52-Week Range: 14.69 - 18.26
1-Month: +0.50% 1-Year: +14.32% 5-Year: +17.24% Beta vs R2500G: 0.98

Mutual Fund Chart for DBMAX

No chart data available.
  • DBMAX:US 18.08
  • 1M
  • 1Y
Interactive DBMAX Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for DBMAX

Dreyfus/The Boston Company Small/Mid Cap Growth Fund is an open-end fund incorporated in the USA. The Fund seeks long-term growth of capital. The Fund invests at least 80% of its net assets in equity securities of small- and mid-cap U.S. companies.

Inception Date: 03-31-2009 Telephone: 1-800-346-8893 Domestic
Managers: ROBERT ZEUTHEN / TODD W WAKEFIELD
Web Site: public.dreyfus.com

Fundamentals for DBMAX

NAV (on 2015-05-27) 18.08
Assets (M) (on 2015-05-27) 982.09
Fund Leveraged N
Minimum Investment 1,000.00
Minimum Subsequent Investment 100.00

Dividends for DBMAX

No dividends reported

Fees & Expenses for DBMAX

Front Load 5.75
Back Load 1.00
Current Mgmt Fee 0.60
Redemption Fee 0.00
12b1 Fee 0.00
Expense Ratio 1.04

Top Fund Holdings for DBMAX

Filing Date: 02/28/2015
Name Position Value % of Total
Synopsys Inc 407,959 18,933,377 2.032%
Jazz Pharmaceuticals PLC 105,006 17,860,471 1.917%
ACADIA Pharmaceuticals Inc 438,687 16,656,945 1.787%
Advisory Board Co/The 298,574 16,158,825 1.734%
Airgas Inc 130,566 15,304,947 1.642%
Watsco Inc 129,054 15,130,291 1.624%
Celldex Therapeutics Inc 580,929 14,836,927 1.592%
Jarden Corp 279,266 14,820,647 1.590%
Align Technology Inc 256,355 14,701,959 1.578%
Akamai Technologies Inc 211,466 14,699,002 1.577%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil